GLP-1 & Incretin Science

Where a Peptide Stops Being a Drug

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

The FDA treats an alpha-amino acid polymer of 40 residues or fewer as a peptide, regulated as a drug. Anything longer is a protein, regulated as a biologic. Semaglutide is 31 residues, which places it on the drug side of that line.

Key facts

Threshold
40 amino acids
40 or fewer
Peptide, regulated as a drug
More than 40
Protein, regulated as a biologic
Semaglutide
31 residues (a drug)
IGF-1 LR3
83 residues (protein territory)
Generic route for drugs
ANDA, bioequivalence
Generic route for biologics
Biosimilar, higher burden

Why a line has to be drawn somewhere

Small molecules can be characterised completely: every atom, every bond, confirmed by analysis. Large proteins cannot, because their behaviour depends on folding and post-translational modification that no analytical method fully captures. Regulation treats these differently, and peptides sit between them, so a boundary is needed and any boundary will be somewhat arbitrary.

Why 40 is a reasonable place for it

Below roughly that length a molecule can generally be made by chemical synthesis and characterised to the atom. Above it, synthesis becomes progressively harder (coupling efficiency compounds, so a 40-mer at 99% per step finishes around 68% full-length before purification) and folding starts to matter. The number marks where full characterisation stops being achievable.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What the classification changes

The route a generic takes. A drug generic files an ANDA and demonstrates bioequivalence, meaning that it delivers the same active ingredient at the same rate and extent. A biosimilar must demonstrate no clinically meaningful difference from the reference product, which usually requires comparative clinical work. The second is far slower and far more expensive.

The subtlety about manufacturing route

The FDA accepts that an ANDA applicant may show a proposed synthetic peptide is the same as the active ingredient in a previously approved peptide of recombinant DNA origin. So a generic can be chemically synthesised while the innovator was made recombinantly, and still be the same active ingredient. Sameness is judged on the molecule, not on how it was produced.

Where this catalogue falls either side of the line

Semaglutide at 31 residues and tirzepatide at 39 are both drugs. Retatrutide at 39 likewise. IGF-1 LR3 at 83 residues sits well past the threshold and would be handled as a biologic, which is consistent with it being a recombinant product with the impurity profile and folding concerns that come with one.

What none of this means for research material

Nothing supplied here holds any classification at all, because it holds no marketing authorisation. The drug-versus-biologic distinction governs how licensed medicines are approved and how their generics reach patients. It does not describe research chemicals, which sit outside that framework entirely.

Quick reference

CompoundResiduesClassification
Semaglutide31Peptide (drug)
Tirzepatide39Peptide (drug)
Retatrutide39Peptide (drug)
IGF-1 LR383Protein territory (biologic)

Frequently asked questions

Is Ozempic a biologic?

No. Semaglutide is 31 amino acids, and the FDA treats 40 or fewer as a peptide regulated as a drug.

Why does the classification matter?

Drug generics file an ANDA showing bioequivalence. Biosimilars must show no clinically meaningful difference from the reference, which is far slower and costlier.

Can a synthetic generic reference a recombinant innovator?

Yes. The FDA accepts that sameness can be demonstrated across manufacturing routes; it is judged on the molecule.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.